Monoclonal Antibody News and Research

RSS

Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.

Researchers identify novel therapeutic monoclonal antibodies from Zika-infected patients

A team of researchers from the Institute for Research in Biomedicine and the Swiss biotech company Humabs BioMed SA has identified novel therapeutic monoclonal antibody candidates isolated from Zika-infected patients and new strategies for Zika virus diagnostics.

14 Jul 2016

Study finds evidence that PD-1 antibody may benefit men with metastatic prostate cancer

Restoring tumor-specific immunity is a treatment strategy that works well in melanoma and lung cancer patients. Now a new study out of the OHSU Knight Cancer Institute is reviving hope that the approach also may help men with life-threatening prostate cancer.

14 Jul 2016

H3N2v-neutralizing antibodies produced from human subjects given candidate vaccine

Influenza A viruses are responsible for seasonal disease outbreaks in humans. Influenza A also circulates among bird and some mammal populations and periodically crosses between species.

8 Jul 2016

Necitumumab drug shows minor added benefit in patients with metastatic NSCLC

The monoclonal antibody necitumumab has been approved since February 2016 for the treatment of patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) expressing non-small cell lung cancer (NSCLC) who have not received prior chemotherapy for this condition.

5 Jul 2016

Celltrion Healthcare commits to develop lab tests for evidence-based decision-making in anti-TNF treatment

Celltrion Healthcare, a global biopharmaceutical company, today announced its research commitment to develop laboratory tests that will determine both drug and anti-drug antibody levels in the blood, enabling physicians to identify when patients on an anti-tumour necrosis factor drug require a change of dose or a switch to a different treatment in the class.

5 Jul 2016

TAILOR study shows treatment with Erbitux plus FOLFOX improves survival in RAS wild-type mCRC patients

Merck, a leading science and technology company, will present data at the ESMO 18th World Congress on Gastrointestinal Cancer from the pivotal Phase III TAILOR study in patients from China, the first prospective trial to evaluate an anti-EGFR antibody in the first-line therapy of patients with RAS wild-type metastatic colorectal cancer (mCRC).

4 Jul 2016

Novel anti-interleukin 1-alpha antibody shows promise in treating advanced colorectal cancer patients

A novel anti-interleukin 1-alpha antibody has shown a significant impact on symptoms, and a high level of safety and tolerability in patients with advanced colorectal cancer, according to phase III data presented at the European Society for Medical Oncology's 18th World Congress of Gastrointestinal Cancer in Barcelona, Spain.

4 Jul 2016

Novel therapeutic approach may be effective for disrupting bacterial biofilms

Biofilms are communities of bacteria that adhere to a surface and are nearly impossible to eradicate when they are pathogenic, or disease-causing.

30 Jun 2016

Switch to rituximab shows anti-inflammatory effect in relapsing-remitting MS

Rituximab may be an attractive treatment option for patients with relapsing-remitting multiple sclerosis, suggest phase II study findings showing its efficacy in controlling inflammatory activity.

22 Jun 2016

FDG-PET imaging tracks ability of atezolizumab to bolster immunity against NSCLC

Non-small cell lung cancers have a collective reputation for not responding very well to chemotherapy. Researchers at the 2016 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) are presenting a means of evaluating an immunotherapy that fights off NSCLC by strengthening a patient's own immune system.

14 Jun 2016

Dr. Pinchas Tsukerman earns prestigious Kaye Innovation Award for research on cancer immunotherapy

The importance of the body's immune system in protecting against the creation of cancerous tumors has been known for a long time. But despite the existence of a competent immune system, some individuals develop tumors, in part because tumors have ways to evade destructive immunity or induce immune-suppression.

9 Jun 2016

Study provides insights into new pathways to generate universal vaccine against influenza viruses

Diverse antibodies induced in humans by vaccination with an avian influenza virus vaccine may offer broader, more durable protection against multiple strains of influenza than today's vaccines typically provide, according to a study led by Florian Krammer, PhD, Assistant Professor in the Department of Microbiology at the Icahn School of Medicine at Mount Sinai, and Patrick Wilson, PhD, Associate Professor in the Department of Medicine at the University of Chicago.

9 Jun 2016

Migraine drug has quick onset of action

The drug TEV-48125, shown to be effective for chronic migraine in a phase II trial, appears to work within 3 to 7 days of injection, researchers report.

9 Jun 2016

IQWiG examines whether ramucirumab drug offers added benefit for MCRC and NSCLC patients

Ramucirumab is a monoclonal antibody, which blocks a receptor, reducing the growth of blood vessels and so reducing blood supply to the tumours.

6 Jun 2016

Women undergoing breast cancer treatment are not getting recommended follow-up heart scans

Despite the known toxic effects of chemotherapy on the heart, the majority of women undergoing breast cancer treatment are not getting the recommended follow-up heart scans, according to research presented at the British Cardiovascular Society Conference in Manchester today.

6 Jun 2016

Immunotherapy with experimental monoclonal antibody could reduce neuroblastoma tumors

Neuroblastoma tumors shrank, some dramatically, in 80 percent of newly diagnosed, young, high-risk patients enrolled in a Phase II clinical trial that included an experimental monoclonal antibody. The immunotherapy agent was produced on the St. Jude Children's Research Hospital campus where the study is still underway.

3 Jun 2016

Monoclonal Antibody News and Research

Further Reading

Researchers identify novel therapeutic monoclonal antibodies from Zika-infected patients

Study finds evidence that PD-1 antibody may benefit men with metastatic prostate cancer

H3N2v-neutralizing antibodies produced from human subjects given candidate vaccine

Necitumumab drug shows minor added benefit in patients with metastatic NSCLC

Celltrion Healthcare commits to develop lab tests for evidence-based decision-making in anti-TNF treatment

TAILOR study shows treatment with Erbitux plus FOLFOX improves survival in RAS wild-type mCRC patients

Novel anti-interleukin 1-alpha antibody shows promise in treating advanced colorectal cancer patients

Novel therapeutic approach may be effective for disrupting bacterial biofilms

Switch to rituximab shows anti-inflammatory effect in relapsing-remitting MS

FDG-PET imaging tracks ability of atezolizumab to bolster immunity against NSCLC

Dr. Pinchas Tsukerman earns prestigious Kaye Innovation Award for research on cancer immunotherapy

Study provides insights into new pathways to generate universal vaccine against influenza viruses

Migraine drug has quick onset of action

IQWiG examines whether ramucirumab drug offers added benefit for MCRC and NSCLC patients

Women undergoing breast cancer treatment are not getting recommended follow-up heart scans

Immunotherapy with experimental monoclonal antibody could reduce neuroblastoma tumors

Additional drug treatment options to prevent migraine may offer hope to sufferers

Oncologists to present latest research findings at ASCO annual meeting

DECT trial shows combination of epirubicin and trastuzumab improves outcomes in breast cancer patients

Phase I study of triple drug combination shows promise in multiple myeloma patients

Antibodies eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®